Congratulations!
You've Taken Your 1st Step In Your Weight Loss Journey
You don't appear to have any contraindications and are a good candidate for GLP-1 medications based on your answers in the initial pre-screen. It will be smooth sailing from here.
We just sent an email with the results from your initial pre-screen showing how much weight you could lose with Made Ya Skinny and a recap of these instructions for your refence. Make sure to check your spam and add us to your safe-senders list!
At Made Ya Skinny, patients using tirzepatide from our accredited compounding pharmacies typically lose an average of 7–10 pounds per month—significantly outpacing standard expectations. While individual results may vary, every client so far has experienced measurable weight loss through this program.
NOW IT'S TIME TO CHOOSE YOUR OWN ADVENTURE
TELEHEALTH OR IN-PERSON?
NEXT STEP For local patients:
Make a Reservation to come in and we will do your exam, 3D body scan, health assessment, and medications in office.
Ready to fast-track your journey? Buy tirzepatide or semaglutide on our Products Page. After your telehealth exam, reserve a time at our Conroe or Cypress clinic for your scan and to pick up your meds. Hybrid care made easy—online convenience with in-person support.
Note: If you’re just starting your weight loss journey with compounded tirzepatide, be sure to select 2.5mg–10mg from the dropdown. Higher doses typically aren’t needed until around month 5 or later.
NEXT STEP For Telehealth Patients:
Your next step is to continue to Telehealth and purchase your chosen medication—either tirzepatide or semaglutide. After your purchase, you’ll receive an email with a link to complete your medical exam with one of our licensed telehealth providers. Once you’re medically cleared, your prescription will be sent to one of our accredited partner pharmacies, and your medication will be shipped directly to your door. EZ BREEZY!!
Should you have any additional questions, chat with us online or reserve a time to speak with a team member. Thank you and we look forward to going on this journey with you and together we can say "Adios Adipose!"
*Reference list
Wilding J.P.H., et al. “Once‑Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” New England Journal of Medicine 384, no. 11 (2021): 989‑1002. DOI: 10.1056/NEJMoa2032183.
Full text: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 (New England Journal of Medicine)
Jastreboff A.M., et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT‑1).” New England Journal of Medicine 387, no. 3 (2022): 205‑216. DOI: 10.1056/NEJMoa2206038.
Full text: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 (New England Journal of Medicine)
Cosentino C., et al. “Triple‑Hormone‑Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine 389, no. 8 (2023): 673‑686. DOI: 10.1056/NEJMoa2301972.
Full text: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 (New England Journal of Medicine)
Note on numbers:
Wegovy® (semaglutide) – ≈ 12 % mean weight reduction at 68 weeks (STEP 1).
Zepbound® (tirzepatide, 15 mg) – ≈ 17 % mean reduction at 72 weeks (SURMOUNT‑1).
Retatrutide 32 mg – ≈ 24 % mean reduction at 48 weeks; projected to ~32 % at 72 weeks in dose‑response modelling (same study).